肺鳞状细胞癌的分子通路研究进展

Abstract
Figure/Table
References (34)
Related Citation (12)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract The national smoking has been at a higher level for a long time and with the prevalence of electronic cigarette in the crowd of young people, due to the close relationship between lung squamous cell carcinoma (SQCC) and smoking, smoking is one of the most important risk factors for lung SQCC, therefore, lung SQCC will occupy a pivotal position among the lung cancer population in China. Through the analysis of recent studies on genes and molecular signaling pathways related to abnormal expression of lung epithelial squamous metaplasia and canceration in databases such as PubMed and Wiley, this paper elaborated a number of molecular pathway mechanisms related to the occurrence of lung SQCC, and summarized new and more valuable experimental studies on molecular pathways related to the occurrence of lung SQCC and the progress of corresponding pathway target drugs in recent years, aiming at introducing some new developments and possible drug research directions of the current lung SQCC generation mechanism and targeted therapy.

Key words： Squamous cell carcinoma Molecular pathway Pathogenesis Targeted therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TANG Yi
	JIN Yi-feng

Cite this article:

TANG Yi,JIN Yi-feng. Research progress of molecular pathways in lung squamous cell carcinoma[J]. 中国当代医药, 2020, 27(16): 14-18.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I16/14

[8]	Adrian TE，Collin P.The anti-cancer effects of Frondoside A[J].Mar Drugs，2018，16（2）：E64.
[16]	Krause G，Winkler L，Mueller SL，et al.Structure and function of claudins[J].Biochim Biophys Acta，2008，1778（3）：631-645.
[1]	Travis WD，Brambilla E，Nicholson AG，et al.The 2015 World Health Organization Classification of lung tumors：impact of genetic，clinical and radiologic advances since the 2004 Classification[J].J Thorac Oncol，2015，10（9）：1243-1260.
[2]	Ettinger DS，Aisner DL，Wood DE，et al.NCCN guidelines insights：non-small cell lung cancer，Version 5.2018[J].J Natl Compr Canc Netw，2018，16（7）：807-821.
[3]	Lu YQ，Lu KH.Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer[J].Chronic Dis Transl Med，2017，3（1）：1-7.
[4]	Radu M，Semenova G，Kosoff R，et al.PAK signalling during the development and progression of cancer[J].Nat Rev Cancer，2014，14（1）：13-25.
[5]	Aguilar-Aragon M，Elbediwy A，Foglizzo V，et al.Pak1 kinase maintains apical membrane identity in epithelia[J].Cell Rep，2018，22（7）：1639-1646.
[6]	Chung JH，Kim DH，Kim YS，et al.Upregulation of p21-activated kinase 1（PAK1）/CREB axis in squamous non-small cell lung carcinoma[J].Cell Physiol Biochem，2018，50（1）：304-316.
[7]	Attoub S，Arafat K，Gelaude A，et al.Frondoside a suppressive effects on lung cancer survival，tumor growth，angiogenesis，invasion，and metastasis[J].PLoS One，2013，8（1）：e53087.
[9]	Huang HW，Zhang XY，Song PL，et al.Old drug new tricks：Chlorhexidine acts as a potential allosteric inhibitor toward PAK1[J].Biochem Biophys Res Commun，2018，495（1）：728-732.
[10]	Ito M，Codony-Servat C，Codony-Servat J，et al.Targeting PKCiota-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma[J].Cell Commun Signal，2019，17（1）：137.
[11]	Gontan C，De Munck A，Vermeij M，et al.Sox2 is important for two crucial processes in lung development：Branching morphogenesis and epithelial cell differentiation[J].Dev Biol，2008，317（1）：296-309.
[12]	Kim BR，Van de Laar E，Cabanero M，et al.SOX2 and PI3K cooperate to induce and stabilize a squamous-committed stem cell injury state during lung squamous cell carcinoma pathogenesis[J].PLoS Biol，2016，14（11）：e1002581.
[13]	Mollaoglu G，Jones A，Wait SJ，et al.The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment[J].Immunity，2018，49（4）：764-779.e9.
[14]	Moisés J，Navarro A，Santasusagna S，et al.NKX2-1 expression as a prognostic marker in early-stage non-smallcell lung cancer[J].BMC Pulm Med，2017，17（1）：197.
[15]	Kim BR，Coyaud E，Laurent EMN，et al.Identification of the SOX2 interactome by bioID reveals EP300 as a mediator of SOX2 -dependent squamous differentiation and lung squamous cell carcinoma growth[J].Mol Cell Proteomics，2017，16（10）：1864-1888.
[17]	Paschoud S，Bongiovanni M，Pache JC，et al.Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas[J].Mod Pathol，2007，20（9）：947-954.
[18]	Lv J，Sun B，Mai Z，et al.CLDN-1 promoted the epithelial to migration and mesenchymal transition （EMT） in human bronchial epithelial cells via Notch pathway[J].Mol Cell Biochem，2017，432（1-2）：91-98.
[19]	Akizuki R，Shimobaba S，Matsunaga T，et al.Claudin-5，-7，and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma[J].Biochim Biophys Acta Mol Cell Res，2017，1864（2）：293-302.
[20]	Li X，Iida M，Tada M，et al.Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy[J].J Pharmacol Exp Ther，2014，351（1）：206-213.
[21]	Mueckler M，Caruso C，Baldwin SA，et al.Sequence and structure of a human glucose transporter[J].Science，1985，229（4717）：941-945.
[22]	Goodwin J，Neugent ML，Lee SY，et al.The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition[J].Nat Commun，2017，8：15 503.
[23]	Jiang T，Zhou ML，Fan J.Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro[J].Onco Targets Ther，2018，11：7865-7872.
[24]	Mi YJ，Geng GJ，Zou ZZ，et al.Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells[J].PLoS One，2015，10（3）：e0120426.
[25]	Chen HF，Wu LX，Li XF，et al.Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1α-mediated glucose metabolism[J].Cell Mol Biol（Noisy-le-grand），2019，65（4）：48-52.
[26]	Wang H，Yang X，Zhao C，et al.Glucose-conjugated platinum（IV） complexes as tumor-targeting agents：design，synthesis and biological evaluation[J].Bioorg Med Chem，2019，27（8）：1639-1645.
[27]	Holtrich U，Wolf G，Brauninger A，et al.Induction and down-regulation of PLK，a human serine/threonine kinase expressed in proliferating cells and tumors[J].Proc Natl Acad Sci USA，1994，91（5）：1736-1740.
[28]	Li H，Wang H，Sun Z，et al.The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients：immunohistochemical analysis[J].Biosci Rep，2017，37（4）：pii：BSR20170852.
[29]	Lee JK，Ha GH，Kim HS，et al.Oncogenic potential of BEX4 is conferred by Polo-like kinase 1-mediated phosphorylation[J].Exp Mol Med，2018，50（10）：1-12.
[30]	Zhang T，Xin G，Jia M，et al.The Plk1 kinase negatively regulates the Hedgehog signaling pathway by phosphorylating Gli1[J].J Cell Sci，2019，132（2）：pii：jcs220384.
[31]	De Blasio C，Zonfrilli A，Franchitto M，et al.PLK1 targets NOTCH1 during DNA damage and mitotic progression[J].J Biol Chem，2019，294（47）：17 941-17 950.
[32]	Rubner S，Scharow A，Schubert S，et al.Selective degradation of Polo-like kinase 1 by a hydrophobically tagged inhibitor of the polo-box domain[J].Angew Chem Int Ed Engl，2018，57（52）：17 043-17 047.
[33]	Li Z，Zhang Z，Sun H，et al.Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1[J].Bioorg Chem，2019，91：103 148.
[34]	Cancer Genome Atlas Research Network.Comprehensive genomic characterization of squamous cell lung cancers[J].Nature，2012，489（7417）：519-525.